Navigation Links
Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))

TOKYO, October 22 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a binding letter of agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialization of the emergency contraceptive pill SOH-075 (NorLevo(R)).

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse. NorLevo(R) was first launched in Europe in 1999 and is currently approved in some 60 countries; the product being both safe and effective as an oral emergency contraceptive for post-coital use. Sosei acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The Phase III study was completed in October 2008, and filing of the NDA in Japan is planned for the first half of 2009.

Under the terms of the agreement Sosei will be responsible for Development and registration and ASKA for sales and marketing. A joint committee will be established to oversee all the commercialisation activities. As part of the deal structure, Sosei will receive upfront and milestone payments as well as a significant portion of net sales. ASKA will also acquire shares of Sosei.

With its current product line-up, which includes oral contraceptive pills and infertility drugs, ASKA has taken a significant share of the Japanese obstetric and gynaecologic market. Now, as the anticipated marketing of a menopause disorder patch at the beginning of 2009 approaches, ASKA is focusing on further enhancement of its position in these therapeutic areas.

The agreement underscores Sosei's wish to make a contribution to women's health in Japan.

Notes to Editors


ECP is necessary for women who may be concerned about the possibility of an unwanted pregnancy following unprotected intercourse. Two large multinational studies, aiming to test a 12-24h regimen (Lancet, 1999) and a single administration (Lancet, 2002), both performed by the World Health Organisation (WHO) demonstrated that levonorgestrel mono therapy, such as NorLevo(R), was safe and more effective than the Yuzpe method (ethinyl estradiol and levonorgestrel), a traditional emergency contraception method used since 1977. Levonorgestrel mono therapy for emergency contraception is listed as an essential drug by the WHO.

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sosei Announces Outcome of Strategy Review
2. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
3. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
4. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
5. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
6. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
7. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
8. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
9. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today ... Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an ... turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of turfgrass ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... ... , ... The Academy of Model Aeronautics (AMA), led by its Executive Council, ... Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing has ... type of racing and several new model aviation pilots have joined the community because ...
Breaking Biology Technology:
(Date:11/19/2015)... Calif. , Nov. 19, 2015  Based on ... Frost & Sullivan recognizes BIO-key with the 2015 Global ... Each year, Frost & Sullivan presents this award to ... line catering to the needs of the market it ... product line meets and expands on customer base demands, ...
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
Breaking Biology News(10 mins):